Insightec
| Private | |
| Industry |
Medical devices, Magnetic Resonance guided Focused Ultrasound |
| Founded | 1999 |
| Headquarters |
Tirat Carmel, Israel Dallas, USA |
Area served | Worldwide |
Key people | Dr. Jacob Vortman, (CEO) |
| Products |
Exablate Exablate Neuro |
| Website | Insightec.com |
INSIGHTEC Ltd., was founded in 1999, by Dr. Jacob (Kobi) Vortman and Mr. Oded Tamir. Dr. Vortman, holds a Ph.D. In Electrical Engineering (in the area of Electro-Optics) from the Technion Israel Institute of Technology, was the founder and innovator of the technology. Insightec Ltd. is a privately held company owned by Elbit Medical Imaging, GE Healthcare, private investors and employees. INSIGHTEC was founded specifically to develop MR (magnetic resonance) guided Focused Ultrasound technology. Headquartered in Tirat Carmel near Haifa, Israel, with US headquarters in Dallas Texas, the company has over 160 employees.[1]
The company's portfolio ranges through three main clinical areas: Women's Health, Oncology and Neurosurgery.
Technology
INSIGHTEC developed Exablate – a therapy platform that combines Magnetic Resonance Imaging and Focused Ultrasound to non-invasively treat tumors inside the body without the need for incisions. During this outpatient procedure, the patient lies inside an MRI scanner, which provides three-dimensional images of the diseased tissue and surrounding area, enabling precise guidance of the ultrasound waves. High intensity focused ultrasound waves are then directed into the body at specific tissue, raising the temperature of the targeted tissue to 65 to 85 degrees Celsius, destroying it. The imaging capabilities of the MRI scanner provide real-time feedback on all aspects of the procedure which gives the physician a high degree of control over its therapeutic outcome.
Exablate has been approved to treat symptomatic uterine fibroids, and bone metastasis, and is currently in use in many medical centers throughout the US, Israel, Europe and Asia. Clinical trials are being conducted to evaluate Exablate for treatment of other diseases such as prostate, liver, and brain cancers.
Exablate Neuro has been CE marked to treat essential tremor, Parkinson's Disease associated tremor and Neuropathic Pain. It is currently under FDA investigation for the treatment of essential tremor and clinical trials are being conducted to evaluate the safety and efficacy of Exablate Neuro for treatment of Parkinson's Disease associated tremor.
See also
External links
References
- ↑ "InSightec, Ltd.: Private Company Information", BusinessWeek, retrieved 2010-04-30